Skip to main content
Signal8
Launch Terminal

Entera Bio Ltd. (ENTX)

Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Entera Bio Ltd. logo

Entera Bio Ltd.

NASDAQ:ENTXHealthcare
+2.56%$3.20
AH$3.22+0.61%vs close
Mkt Cap$556.55M
Float159.35M
O/S173.92M
Vol
$ Vol
RVOL
Inst Own2.8%
SI3.5%
Earnings
Dilution
Entera Bio Ltd. logoNASDAQ:ENTX$3.20+2.56%
Phase Distribution
6 lead-sponsored trials·0 active·6 completed
Phase 13
Phase 23
Status Overview
Completed6

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Phase
  • Phase 2
    Completed

    A Pilot Study to Assess the Safety and Efficacy of Oral PTH (1-34) in the Treatment of Hypoparathyroidism

    EnteraBio's Oral Parathyroid Hormone (1-34)

    Hypoparathyroidism

    Enrollment
    20
    Start
    Jul 2014
    Primary Completion
    Jun 2015
    Completion
    Jul 2015
    NCT02152228
  • Phase 2
    Completed

    Oral PTH(1-34) PK and PD Study in Patients With Hypoparathyroidism

    EB612 (EBP05), NATPARA/NATPAR

    Hypoparathyroidism

    Enrollment
    20
    Start
    Jun 2018
    Primary Completion
    Dec 2018
    Completion
    Feb 2019
    NCT03516773
  • Phase 2
    Completed

    A Six-month Phase 2 Study of Oral hPTH(1-34) (EBP05) in Postmenopausal Women With Low Bone Mass

    EBP05, Placebo of EBP05

    Osteoporosis

    Enrollment
    161
    Start
    Jun 2019
    Primary Completion
    Apr 2021
    Completion
    May 2021
    NCT04003467
  • Phase 1
    Completed

    A Three Stage, Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Oral PTH (1-34) in Healthy Subjects

    Teriparatide, Teriparatide

    Drug Safety

    Enrollment
    42
    Start
    Jul 2011
    Primary Completion
    Aug 2013
    Completion
    Aug 2013
    NCT02202603
  • Phase 1
    Completed

    A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Oral PTH (1-34) Formulations in Healthy Subjects

    Teriparatide, Oral PTH (1-34)

    Drug Safety and Bioavailability

    Enrollment
    30
    Start
    Oct 2013
    Primary Completion
    Aug 2017
    Completion
    Oct 2017
    NCT02571140
  • Phase 1
    Completed

    Assess Safety and Compare PK of New Oral hPTH(1-34) Tablet Formulations vs. EBP05 Tablets and Subcutaneous Forteo

    EBP05, Forteo 0.02 mg

    Hypoparathyroidism, Osteoporosis +2

    Enrollment
    45
    Start
    May 2023
    Primary Completion
    Feb 2026
    Completion
    Feb 2026
    NCT05965167
Search ClinicalTrials.gov for “Entera Bio”